The Human Variable 

Using CYNAERA’s US-CCUC™ model, we present a corrected demographic landscape grounded in published science, epidemiological data, and terrain-calibrated prevalence modeling. For the first time, undocumented immigrant populations and ancestral dietary biology are incorporated as visible drivers of disease prevalence. Our analysis demonstrates that half of Americans with ME/CFS are non-white, and that prevalence in certain groups is likely higher when adjusted for baseline into

Using CYNAERA’s recalibrated tiered prevalence model, weighted for environmental exposure, access to paid sick leave, and diagnostic inequity, we estimate that around 14.4 million Americans currently meet the diagnostic criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

CYNAERA’s US-CCUC™ (Chronic Condition Undercount Correction – U.S.) model provides a corrected formula for estimating the real burden of ME/CFS. It builds on pre-pandemic cases, integrates the Long COVID surge, and corrects for the 80–90% of patients who were always there — but never diagnosed. Whether you lean on the cautious estimate of ~9.5 million Americans or the more realistic ~21.5 million, the message is the same: ME/CFS is a condition that rivals the scale of diabete

The Global-CCUC™ (Chronic Condition Undercount Correction – Global) model provides a recalibrated framework. By weighting diagnostic suppression, environmental terrain, social protections, clinical awareness, and pandemic burden, it reveals a truer picture: 94–127 million conservative cases and 220–290 million upper-bound cases worldwide.

The CDF-ME framework captures between 88–94% of patients who meet International Consensus Criteria (ICC), Canadian Consensus Criteria (CCC), or the National Academies of Sciences, Engineering, and Medicine (NASEM) diagnostic criteria, regardless of whether their illness was triggered by infection, vaccination, physical trauma, or environmental exposure. Validated through CYNAERA’s AI engine and over 200,000 patient simulations, CDF-ME integrates high-specificity markers .

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio